dMMR/MSI-H Rectal Cancer

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

dMMR/MSI-H Rectal Cancer

Dec 21, 2024, 05:01 | Insight

FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer

The FDA has granted Breakthrough Therapy Designation (BTD) to dostarlimab for the treatment of patients…

All: 1 Posts: 1 - 100

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

'

King Charles III Hospitalized Following Side Effects from Cancer Treatment

'

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

'

MARIPOSA trial results presented at ELCC25 - BREAKING from Paris

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023